When cancer is diagnosed, finding treatment options is the top priority
OncoTarget® Series is our comprehensive genomic profiling solution to identify targeted immunotherapies for advanced cancers– solid tumors or leukemias.
Learn about our newly launched, FDA cleared, 500-gene panel - OncoTarget® 500*
OncoTarget® Series Test Menu
FDA cleared gene panel testing

  • Cleared for all solid tumors
  • 100% clinical biomarkers covered
  • Includes: CDx, NCCN guideline-directed targeted genes
  • Cost-effective
  • Timely
Your confidence is found within OncoTarget’s
multi-technology platform
MSI and Single Mutations
next-generation sequencing
#ASCO22 week is here and we are excited to announce the release of our FDA-Cleared CGP Test under OncoTarget® 500.

Visit us in booth #28109 on June 4-6 between 9:00 AM–5:00 PM each day and learn how this CGP solution will help advance cancer treatments by identifying genomic targets for both targeted therapy and immunotherapy.